Ms. Dawson is Senior Vice President and Program Team Lead for seralutinib, leading both the Gossamer development team and the joint partnership development team with Chiesi. Ms. Dawson has over 25 years of research and development experience in biotechnology, progressing from technical roles into management oversight of product development and CMC / Technical Operations organizations. Ms. Dawson has held various roles in Gossamer’s CMC organization since joining in April 2018, most recently as Vice President of Technical Operations before transitioning into her current role in late 2023. Prior to joining Gossamer Bio, Ms. Dawson held a CMC leadership role at Receptos, Inc, leading to the successful completion of multiple global Phase 3 clinical trials and commercial approval of ozanimod (Zeposia, Celgene/BMS), as well as leading the integration efforts for supply chain with Celgene (post-Receptos acquisition by Celgene). Previously, Ms. Dawson held multiple prior roles in product development and engineering, notably with other drug / device combination products like seralutinib, including OP-1 Implant (BMP-7) for fracture healing (Stryker Biotech), and TAR-200 (Janssen) for intravesical delivery of gemcitabine. Ms. Dawson completed her master’s and bachelor’s degrees in Biomedical Engineering at Virginia Tech.